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Upregulation and function of GADD45c in unilateral
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We performed differential display analysis to determine
transcriptional activity in the rat kidney, following unilateral
ureteral obstruction and found a 12-fold increase in the
expression of Growth Arrest and DNA Damage-45c
(GADD45c), a stress-responsive molecule that interacts with
cell-cycle proteins. GADD45c was strongly expressed in as
little as 6 h following ureteric obstruction in the renal tubules,
and was also found in kidney tissue of patients with chronic
glomerulonephritis. Adenovirus-mediated expression of
GADD45c in cultured renal tubular cells activated p38 along
with a significant upregulation of C–C and C–X3–C chemokine
ligands and fibrosis-related factors such as several matrix
metalloproteinases, transforming growth factor-b1, decorin,
and bone morphogenetic protein 2. Silencing of GADD45c
expression significantly blunted the upregulation of these
inflammatory and fibrogenic mediators and monocyte
infiltration in the ureteral obstructed rat kidney. Our study
shows that GADD45c is quickly upregulated in the kidney
with an obstructed ureter, enhancing the production of
factors regulating the pathogenesis of kidney disease.
Kidney International (2008) 73, 1251–1265; doi:10.1038/ki.2008.93;
published online 19 March 2008
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Growth Arrest and DNA Damage-45 (GADD45) family of
genes has three isoforms, GADD45a, GADD45b, and
GADD45g. GADD45a (¼GADD45) was first identified after
ultraviolet light-mediated DNA damage to Chinese hamster
ovary cells,1 and two other human isoforms were isolated
afterwards and were designated as GADD45b (¼MyD118)
and GADD45g (¼CR6).2 The GADD45 proteins are
evolutionarily conserved and are about 55–58% identical at
the amino-acid level.2 These proteins have been located
mainly in the cell nucleus and less abundantly in the
cytoplasm.2,3 They are induced in response to DNA damage
and environmental stresses and interact with various proteins
involved in cell-cycle regulation.4 With regard to kidney
diseases, data on the role of GADD45 proteins are scarce.
Here, we provide evidence that GADD45g is upregulated in
unilateral ureteral obstruction (UUO) and it regulates
various molecules implicated in the pathogenesis of kidney
diseases.
RESULTS
Differential display analysis
We cloned and sequenced 37 genes that were differentially
expressed in the kidney 1 day post-UUO and found that
18 genes were relevant to rat DNA (data not shown). We
performed a gene-specific polymerase chain reaction (PCR)
for those rat genes using multiple kidney samples, and results
were normalized to glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) expression levels. We found that GADD45g
is a molecule that is significantly upregulated in the cortex of
the UUO kidneys.
GADD45c mRNA expression during the course of UUO
We serially examined the changes of GADD45g expression
during the course of UUO from 6 h through 5 days. The
PCR analysis showed that GADD45g was significantly
increased as early as 6 h post-UUO (B12-fold), gradually
declined thereafter, and remained elevated up to 3 days post-
UUO compared with sham-operated controls (Figure 1).
GADD45g gene expression in the contralateral unobstructed
kidneys was similar to that in the sham-operated kidneys at
all time points of the experiment. We then performed in situ
hybridization to localize GADD45g mRNA in the kidney
tissue 1 day post-UUO. We found that GADD45g was
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Figure 1 | Quantification of mRNA expression of GADD45-family genes in kidneys after UUO by competitive PCR. (a) Competitor
constructs were designed to be flanked by sequences recognized by a pair of target gene-specific primers and to contain an
intervening sequence that differed in size from the target DNA. (b) Rats with UUO (gray bars) were compared with sham-operated controls
(black bars) for each corresponding time. Target gene product amounts were normalized to those of GAPDH, and the results were
expressed as fold changes compared with the controls, n¼ 11–14 for each experimental group. Data are mean±s.e.m.; *Po0.05, **Po0.01
compared with controls. UUO, unilateral ureteral obstruction; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
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strongly induced in the kidney tubules even before they were
dilated (Figure 2). In addition, we examined the other two
members of the GADD45-family genes. Like GADD45g,
GADD45b peaked 6 h post-UUO but with a lesser degree
(up toB3-fold) and for a shorter duration (up to 1 day post-
UUO) compared with GADD45g (Figure 1). By contrast, in
accordance with previous reports,5 GADD45a (¼GADD45)
expression was not increased after UUO (Figure 1).
GADD45c expression in human kidney tissue
To determine whether GADD45g is a relevant molecule in
human kidney disease, we examined GADD45g protein
expression in the kidney biopsy specimens. Immunohisto-
chemistry was performed in 12 cases of chronic glomerulo-
nephritis, including IgA nephropathy and membranous
glomerulonephritis, and in five cases of normal findings.
Positive GADD45g staining was observed in five patients with
chronic glomerulonephritis. The staining was most evident in
tubular cells and was also present in glomerular cells,
interstitial cells, and infiltrating lymphocytes (Figure 3). All
of the patients with normal biopsy findings showed negative
GADD45g immunostaining. These patients were those who
requested kidney biopsy although they had only minor urine
abnormalities. The staining was localized to the nucleus as
expected from immunostaining of cultured cells by other
investigators (Figure 3).4 The specificity of staining was
verified by immunohistochemistry in which the primary
antibody was omitted (data not shown).
Activation of MAPK pathways in HRE cells
To determine whether GADD45g induces activation of
mitogen-activated protein kinase (MAPK) pathways in renal
tubular cells, we infected human renal epithelial (HRE) cells
Sham antisense UUO sense UUO antisense
Figure 2 | Localization of GADD45c mRNA by in situ hybridization. Kidneys were harvested 1 day after UUO or sham operation. Paraffin
sections were treated with the sense (control) or the antisense digoxigenin-labeled RNA probe specific for GADD45g. Strong signals for
GADD45g mRNA were observed in tubular cells of UUO kidneys (UUO antisense) in contrast to weak signals in sham-operated kidneys
(Sham antisense). The sense probe for GADD45g yielded no positive signal (UUO sense). Original magnification  100 in upper panels,
 200 in middle panels,  400 in lower panels. Bars¼ 100 mm.
Figure 3 | GADD45c expression in human kidneys.
Representative kidney biopsy sections demonstrating positive
GADD45g staining (red-purple) in tubular cells (a), glomerular cells
(b), interstitial cells (arrows), and infiltrating lymphocytes
(arrowheads) (c). A normal kidney section with negative GADD45g
staining (d). Only a few exemplary cells are marked with arrows or
arrowheads in each figure. Original magnification  400.
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with recombinant adenoviral vectors containing the
open reading frame, which encodes GADD45g protein
(Ad-GADD45g). First, we infected HRE cells at multiplicities
of infection (MOIs) of 1, 10, 25, 50, 75, and 100 for 24 h; cells
were then harvested and western blotting was carried out to
verify the expression of GADD45g protein. The GADD45g
protein could be detected at an MOI of 25 and above
(Figure 4). Next, we infected HRE cells at MOIs of 1, 10, 100,
and 250 for 24 h and examined the expression of MAPK
proteins. Recombinant adenoviral vectors containing LacZ
(Ad-LacZ) served as control. The result showed that p-p38
MAPK was significantly increased compared with LacZ
controls even at an MOI of 10 where the GADD45g protein
level was below our detection limits. By contrast, phosphory-
lated-c-Jun-N-terminal kinase (P-JNK) and phosphorylated-
extracellular signal-regulated kinase (P-ERK) did not show
any significant changes (Figure 5). These findings suggest that
GADD45g activates the p38 MAPK pathway, but not the
extracellular signal-regulated kinase (ERK) or the c-Jun-N-
terminal kinase (JNK) pathways in renal tubular cells.
Microarray analysis
To further define the function of GADD45g in renal tubular
cells, we infected HRE cells with Ad-GADD45g and Ad-LacZ
and determined differentially expressed genes using micro-
array slides containing 24 000 human genes. The results
showed that the expression level of 164 genes differed by
more that twofold (Table 1). Among those 164 genes, we
selected 12 genes that have been investigated with regard to
pathogenesis of kidney disease, and verified the microarray
results using semiquantitative PCR: these genes include
chemokine (C–C motif) ligand 20 (CCL20), chemokine
(C–X3–C motif) ligand 1 (CX3CL1, fractalkine), interleukin 8
(IL-8), IL-11, matrix metalloproteinase 1 (MMP1), MMP10,
bone morphogenetic protein 2 (BMP2), decorin, integrin-a5,
thrombospondin1, integrin-b1, and collagen XI. Apart from
microarray results, we additionally selected genes that have
been proposed to be implicated in kidney disease progres-
sion; these include collagen I, collagen III, collagen IV,
fibronectin, MMP2, MMP9, monocyte chemotactic protein-
1, vascular endothelial growth factor A, vascular endothelial
growth factor B, connective tissue growth factor, plasmino-
gen activator inhibitor-1, and transforming growth factor-b1
(TGF-b1). After normalization to GAPDH expression, we
were able to identify nine genes whose expression was clearly
altered by GADD45g; these genes were CCL20, CX3CL1,
IL-8, MMP1, MMP9, MMP10, TGF-b1, decorin, and BMP2,
all of which showed significant upregulation (Figure 6).
Next, we examined the production of proinflammatory
chemokines, including CCL20, CX3CL1, and IL-8, in cell
culture media using enzyme-linked immunosorbent assay.
After 24 h of incubation of HRE cells with adenoviral vectors,
cell culture media were collected for analysis. In accordance
with the PCR results, production of all these chemokines
was significantly enhanced by GADD45g in renal tubular
cells (Figure 6).
Apoptosis and proliferation of HRE cells
To investigate the role of GADD45g in apoptosis in renal
tubules, HRE cells were infected with Ad-GADD45g at an
MOI of 500 for 24 h and we evaluated the extent of apoptosis
by detecting poly(ADP-ribose) polymerase (PARP) fragmen-
tation and cleaved DNA with immunoblotting and terminal
deoxynucleotidyl transferase (TdT)-mediated dUTP–biotin
nick-end labeling (TUNEL) staining, respectively. The result
showed absence of TUNEL-positive apoptotic cells and of
cleaved PARP despite strong expression of GADD45g protein
(Figure 7), which indicates that GADD45g may not induce
apoptosis in HRE cells. The role of GADD45g in HRE cell
proliferation was determined using 5-bromo-2-deoxyuridine
(BrdU) labeling and we found that HRE cell proliferation
was significantly reduced in a dose-dependent manner by
GADD45g (Figure 7).
In vivo silencing of the GADD45c gene
To delineate the relationship between GADD45g and
inflammatory and fibrogenic mediators in vivo, we knocked
down the GADD45g gene in the kidney using a ‘hydronamic’
intravenous injection of small interfering RNA (siRNA) into
rats.6–8.Kidneys were harvested 2 days after UUO when
GADD45g and several molecules of interest, such as CCL20,
CX3CL1, cytokine-induced neutrophil chemoattractant-1
(CINC-1, rat homolog for human IL-8),9 TGF-b1, and
p-p38 MAPK, were found to be significantly upregulated
(Figures 1 and 8). In rats injected with GADD45g siRNA,
mRNA expression of GADD45g was inhibited by 90% in
the UUO kidneys compared with that in the controls groups
treated with phosphate-buffered saline (PBS) or negative
control siRNA (Figure 8). The inhibition of GADD45g
resulted in a significant reduction of mRNA expression of
CCL20, CX3CL1, CINC-1, TGF-b1, and p-p38 MAPK in the
UUO kidneys (Figure 8). To evaluate monocyte/macrophage
infiltration into the tubulointerstitium, 20 high-power fields
( 400) per section for each rat (six rats per group) were
obtained from the cortical region and ED1-positive cells were
counted. We found that ED1-positive cells were significantly
reduced in UUO kidneys treated with GADD45siRNA-g
V G1 G10 G25 G50 G75
17 kDa-
Figure 4 | Expression of GADD45c protein in human renal
epithelial cells. Cells were infected with a serial amount of
adenoviral vectors harboring the open reading frame of
GADD45g. After a 24-h incubation, cells were harvested. GADD45g
proteins could be detected at an MOI of 25 and above. V
represents vehicle only and G represents GADD45g. Each number
following G represents an MOI.
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(1.83±0.31 per  400 magnification field) compared with
control UUO kidneys (13.17±1.35 per  400 magnification
field) (Po0.001) (Figure 9).
DISCUSSION
Regardless of the underlying causes, tubulointerstitial fibrosis
is closely associated with disease progression in chronic
kidney disease.10 During this process, tubular cells play a
dominant role by secreting inflammatory and fibrogenic
molecules that are activated by insults.11,12 UUO is a
commonly used animal model of tubulointerstitial injury
and fibrosis.13 Our recent research has been focused on
examining genes that are differentially expressed in the
kidney following UUO, and we found that GADD45g is
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Figure 5 | Activation of p38 MAPK by GADD45c in human renal epithelial cells. After a 24-h incubation with adenoviral vectors, cells
were harvested. GADD45g protein activated p38 but not ERK or JNK. Total MAPK proteins did not show any significant changes. The
intensity of the MAPK protein band was normalized to that of re-probed GAPDH band. Results are the mean of three independent sets of
experiment, n¼ 4 for each experimental group. Data are mean±s.e.m.; *Po0.05 compared with LacZ controls. L represents LacZ; G,
GADD45g. Each number following L or G represents an MOI. MAPK, mitogen-activated protein kinase; ERK, extracellular signal-regulated
kinase; JNK, c-Jun-N-terminal kinase; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
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Table 1 | Genes whose expression is altered by overexpression of GADD45c in human renal epithelial cells
Genes
GenBank
accession Fold±s.d.
B-cell CLL/lymphoma 9 (BCL9), mRNA NM_004326.2 7.66±0.10
Resistin-like-b (RETNLB), mRNA NM_032579.1 7.60±0.18
Interleukin 11 (IL-11), mRNA NM_000641.2 6.69±0.16
Colony-stimulating factor 2 receptor-b, low affinity (granulocyte–macrophage) (CSF2RB), mRNA NM_000395.1 5.29±0.10
Dopamine-b-hydroxylase (dopamine-b-monooxygenase) (DBH), mRNA NM_000787.2 5.05±0.11
Jagged 1 (Alagille syndrome) (JAG1), mRNA NM_000214.1 5.05±0.07
Heat-shock 70-kDa protein 6 (HSP70B0) (HSPA6), mRNA NM_002155.3 5.01±0.16
Heat-shock 70-kDa protein 1B (HSPA1B), mRNA NM_005346.3 4.87±0.11
Heat-shock 70-kDa protein 1A (HSPA1A), mRNA NM_005345.4 4.80±0.10
Zinc finger, AN1-type domain 2A (ZFAND2A), mRNA NM_182491.1 3.99±0.26
Chemokine (C–C motif) ligand 20 (CCL20), mRNA NM_004591.1 3.48±0.12
Growth differentiation factor 15 (GDF15), mRNA NM_004864.1 3.47±0.31
Interleukin 8 (IL-8), mRNA NM_000584.2 3.44±0.38
DnaJ (Hsp40) homolog, subfamily A, member 4 (DNAJA4), mRNA NM_018602.2 3.34±0.03
Inhibin, b-B (activin AB b-polypeptide) (INHBB), mRNA NM_002193.1 3.24±0.08
Somatostatin (SST), mRNA NM_001048.3 3.21±0.14
Histone 1, H2bk (HIST1H2BK), mRNA NM_080593.1 3.12±0.11
Coagulation factor III (thromboplastin, tissue factor) (F3), mRNA NM_001993.2 3.10±0.13
Chemokine (C–X3–C motif) ligand 1 (CX3CL1), mRNA NM_002996.3 3.06±0.22
Regulator of G-protein signalling 4 (RGS4), mRNA NM_005613.3 3.05±0.07
Histone 1, H2bd (HIST1H2BD), transcript variant 2, mRNA NM_138720.1 3.02±0.07
Histone 2, H2ac (HIST2H2AC), mRNA NM_003517.2 2.86±0.26
FK506-binding protein 4, 59 kDa (FKBP4), mRNA NM_002014.2 2.76±0.29
Matrix metallopeptidase 1 (interstitial collagenase) (MMP1), mRNA NM_002421.2 2.70±0.10
Chorionic somatomammotropin hormone 1 (placental lactogen) (CSH1), transcript variant 3, mRNA NM_022641.2 2.69±0.14
Pregnancy-associated plasma protein A, pappalysin 1 (PAPPA), mRNA NM_002581.3 2.66±0.11
Potassium voltage-gated channel, subfamily G, member 1 (KCNG1), transcript variant 1, mRNA NM_002237.2 2.62±0.22
Histone 1, H1c (HIST1H1C), mRNA NM_005319.3 2.62±0.17
Inhibin, b-E (INHBE), mRNA NM_031479.3 2.57±0.12
Glucosaminyl (N-acetyl) transferase 3, mucin type (GCNT3), mRNA NM_004751.1 2.57±0.16
Dual-specificity phosphatase 5 (DUSP5), mRNA NM_004419.3 2.54±0.05
Histone 2, H2aa (HIST2H2AA), mRNA NM_003516.2 2.54±0.15
Crystallin, a-B (CRYAB), mRNA NM_001885.1 2.54±0.07
UDP glycosyltransferase 8 (UDP-galactose ceramide galactosyltransferase) (UGT8), mRNA NM_003360.2 2.53±0.11
ClpB caseinolytic peptidase B homolog (E. coli) (CLPB), mRNA NM_030813.3 2.49±0.12
Serine/threonine kinase 25 (STE20 homolog, yeast) (STK25), mRNA NM_006374.3 2.48±0.27
Chloride intracellular channel 1 (CLIC1), mRNA NM_001288.4 2.47±0.53
Protein phosphatase 1G (formerly 2C), magnesium-dependent, g-isoform (PPM1G), transcript variant 1, mRNA NM_177983.1 2.45±0.19
Hypothetical protein DKFZp564N2472 (DKFZp564N2472), mRNA NM_182595.2 2.45±0.05
Secretogranin II (chromogranin C) (SCG2), mRNA NM_003469.3 2.45±0.07
H2B histone family, member S (H2BFS), mRNA NM_017445.1 2.43±0.16
Transcobalamin I (vitamin B12-binding protein, R binder family) (TCN1), mRNA NM_001062.2 2.42±0.06
Serpin peptidase inhibitor, clade A (a-1 anti-proteinase, antitrypsin), member 3 (SERPINA3), mRNA NM_001085.4 2.39±0.21
Potassium voltage-gated channel, subfamily F, member 1 (KCNF1), mRNA NM_002236.4 2.36±0.28
Tubulin tyrosine ligase-like family, member 11 (TTLL11), mRNA NM_194252.1 2.36±0.25
Dual-specificity phosphatase 1 (DUSP1), mRNA NM_004417.2 2.35±0.18
Heat-shock 105/110-kDa protein 1 (HSPH1), mRNA NM_006644.2 2.32±0.20
BRF2, subunit of RNA polymerase III transcription initiation factor, BRF1-like (BRF2), mRNA NM_018310.2 2.31±0.15
Actin-related protein 2/3 complex, subunit 2, 34 kDa (ARPC2), transcript variant 2, mRNA NM_005731.2 2.31±0.09
Matrix metallopeptidase 10 (stromelysin 2) (MMP10), mRNA NM_002425.1 2.31±0.09
Solute-carrier family 26, member 6 (SLC26A6), transcript variant 3, mRNA NM_134426.1 2.30±0.49
Bone morphogenetic protein 2 (BMP2), mRNA NM_001200.1 2.30±0.06
Mannose-P-dolichol utilization defect 1 (MPDU1), mRNA NM_004870.1 2.28±0.57
Hypothetical protein HSPC111 (HSPC111), mRNA NM_016391.2 2.27±0.29
Hypothetical protein FLJ13639 (FLJ13639), transcript variant 1, mRNA NM_001031719.1 2.26±0.13
N-myc downstream regulated gene 1 (NDRG1), mRNA NM_006096.2 2.26±0.16
Interferon-stimulated exonuclease gene 20 kDa (ISG20), mRNA NM_002201.4 2.25±0.19
MHC class I polypeptide-related sequence B (MICB), mRNA NM_005931.2 2.25±0.37
Interleukin-1 receptor-associated kinase 2 (IRAK2), mRNA NM_001570.3 2.24±0.14
Tubulin, a1 (testis specific) (TUBA1), mRNA NM_006000.1 2.24±0.34
Keratin, hair, acidic, 4 (KRTHA4), mRNA NM_021013.3 2.21±0.09
Decorin (DCN), transcript variant B, mRNA NM_133504.2 2.19±0.05
Histone 1, H3d (HIST1H3D), mRNA NM_003530.3 2.19±0.10
Golgi autoantigen, golgin subfamily a, 2 (GOLGA2), mRNA NM_004486.4 2.18±0.40
Colony-stimulating factor 2 (granulocyte–macrophage) (CSF2), mRNA NM_000758.2 2.17±0.24
Elastin microfibril interfacer 2 (EMILIN2), mRNA NM_032048.2 2.17±0.28
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Table 1 | Continued
Genes
GenBank
accession Fold±s.d.
Runt-related transcription factor 3 (RUNX3), transcript variant 2, mRNA NM_004350.1 2.16±0.14
Hairy and enhancer of split 4 (Drosophila) (HES4), mRNA NM_021170.2 2.16±0.19
Chromosome 22 open reading frame 19 (C22orf19), transcript variant 1, mRNA NM_001002878.1 2.15±0.37
Immediate early response 3 (IER3), transcript variant long, mRNA NM_052815.1 2.15±0.39
AHA1, activator of heat-shock 90-kDa protein ATPase homolog 1 (yeast) (AHSA1), mRNA NM_012111.1 2.14±0.25
Rho/rac guanine nucleotide-exchange factor (GEF) 2 (ARHGEF2), mRNA NM_004723.2 2.14±0.13
Serpin peptidase inhibitor, clade B (ovalbumin), member 1 (SERPINB1), mRNA NM_030666.2 2.14±0.10
Cyclin A1 (CCNA1), mRNA NM_003914.2 2.13±0.09
Major facilitator superfamily domain containing 7 (MFSD7), mRNA NM_032219.2 2.13±0.14
Sema domain, transmembrane domain (TM), and cytoplasmic domain, (semaphorin) 6A (SEMA6A), mRNA NM_020796.2 2.12±0.08
S100 calcium-binding protein A2 (S100A2), mRNA NM_005978.3 2.11±0.15
MCM7 minichromosome maintenance deficient 7 (S. cerevisiae) (MCM7), transcript variant 2, mRNA NM_182776.1 2.10±0.25
Insulin-like growth factor-binding protein 5 (IGFBP5), mRNA NM_000599.2 2.10±0.20
Pleckstrin homology domain containing, family O member 1 (PLEKHO1), mRNA NM_016274.3 2.09±0.32
KIAA0690 (KIAA0690), mRNA NM_015179.2 2.09±0.16
Enolase 2 (g, neuronal) (ENO2), mRNA NM_001975.2 2.09±0.12
Sialic acid-binding Ig-like lectin 7 (SIGLEC7), transcript variant 1, mRNA NM_014385.1 2.09±0.12
Hypothetical protein FLJ90166 (FLJ90166), mRNA NM_153360.1 2.08±0.17
Limb region 1 homolog (mouse)-like (LMBR1L), mRNA NM_018113.1 2.08±0.25
Short stature homeobox (SHOX), transcript variant SHOXb, mRNA NM_006883.1 2.08±0.05
DnaJ (Hsp40) homolog, subfamily B, member 6 (DNAJB6), transcript variant 1, mRNA NM_058246.3 2.08±0.14
SAP30-binding protein (SAP30BP), mRNA NM_013260.5 2.07±0.16
Breast cancer membrane protein 11 (BCMP11), mRNA NM_176813.3 2.07±0.06
Hairy and enhancer of split 1, (Drosophila) (HES1), mRNA NM_005524.2 2.07±0.18
Integrin, a5 (fibronectin receptor, a-polypeptide) (ITGA5), mRNA NM_002205.2 2.07±0.37
Family with sequence similarity 32, member A (FAM32A), mRNA NM_014077.1 2.06±0.44
Transmembrane protein 44 (TMEM44), transcript variant 1, mRNA NM_138399.3 2.05±0.48
ATPase, H+ transporting, lysosomal 31-kDa, V1 subunit E2 (ATP6V1E2), mRNA NM_080653.3 2.05±0.12
Histone 2, H2be (HIST2H2BE), mRNA NM_003528.2 2.05±0.08
Keratin, hair, acidic, 6 (KRTHA6), mRNA NM_003771.3 2.04±0.07
Hypothetical protein FLJ20551 (FLJ20551), mRNA NM_017875.1 2.04±0.23
Dual-specificity phosphatase 4 (DUSP4), transcript variant 2, mRNA NM_057158.2 2.04±0.16
Integrin-b4-binding protein (ITGB4BP), transcript variant 4, mRNA NM_181466.1 2.03±0.25
Signal-induced proliferation-associated 1-like 2 (SIPA1L2), mRNA NM_020808.1 2.02±0.07
RNA-binding motif protein 28 (RBM28), mRNA NM_018077.1 2.01±0.09
Interleukin 23, a-subunit p19 (IL-23A), mRNA NM_016584.2 2.01±0.31
Hypothetical protein LOC283932 (LOC283932), mRNA NM_175901.3 2.01±0.04
VGF nerve growth factor-inducible (VGF), mRNA NM_003378.2 2.01±0.08
N-myristoyltransferase 1 (NMT1), mRNA NM_021079.3 2.00±0.45
Growth arrest and DNA damage-inducible, a (GADD45A), mRNA NM_001924.2 5.82±0.26
Transforming growth factor, b-receptor-associated protein 1 (TGFBRAP1), mRNA NM_004257.3 3.96±0.18
AHNAK nucleoprotein (desmoyokin) (AHNAK), transcript variant 1, mRNA NM_001620.1 3.57±0.72
Phosphoribosyl pyrophosphate synthetase 1 (PRPS1), mRNA NM_002764.2 3.28±0.60
Tubulin, b6 (TUBB6), mRNA NM_032525.1 3.26±0.84
Chromosome 10 open reading frame 65 (C10orf65), mRNA NM_138413.2 3.13±0.12
Protease, serine, 23 (PRSS23), mRNA NM_007173.3 3.01±0.16
CXYorf1-related protein (LOC349338), mRNA NM_182905.1 2.97±0.16
Transmembrane, prostate androgen induced RNA (TMEPAI), transcript variant 1, mRNA NM_020182.3 2.95±0.82
Cytokine-like 1 (CYTL1), mRNA NM_018659.2 2.79±0.13
Thrombospondin 1 (THBS1), mRNA NM_003246.2 2.78±0.62
RAP1, GTPase-activating protein 1 (RAP1GA1), mRNA NM_002885.1 2.77±0.19
Profilin 1 (PFN1), mRNA NM_005022.2 2.75±1.09
Wingless-type MMTV integration site family, member 10A (WNT10A), mRNA NM_025216.2 2.73±0.18
Myosin, light polypeptide kinase (MYLK), transcript variant 6, mRNA NM_005965.3 2.71±0.60
Olfactomedin-like 2A (OLFML2A), mRNA NM_182487.1 2.66±0.15
Lymphocyte antigen 6 complex, locus E (LY6E), mRNA NM_002346.1 2.62±0.48
CD151 antigen (CD151), transcript variant 4, mRNA NM_004357.3 2.59±0.94
Small nuclear ribonucleoprotein polypeptide N (SNRPN), transcript variant 1, mRNA NM_003097.3 2.56±0.85
Ras homolog gene family, member B (RHOB), mRNA NM_004040.2 2.55±0.28
Kv channel interacting protein 1 (KCNIP1), transcript variant 2, mRNA NM_014592.2 2.52±0.26
Cyclin D2 (CCND2), mRNA NM_001759.2 2.52±0.40
Ribosomal protein, large, P0 (RPLP0), transcript variant 2, mRNA NM_053275.3 2.45±0.85
Zinc finger, BED-type containing 2 (ZBED2), mRNA NM_024508.3 2.42±0.14
Small EDRK-rich factor 2 (SERF2), mRNA NM_001018108.1 2.40±0.35
Chromobox homolog 3 (HP1 g homolog, Drosophila) (CBX3), transcript variant 2, mRNA NM_016587.2 2.38±0.87
Actin-like protein (FKSG30), mRNA NM_001017421.1 2.36±0.89
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substantially upregulated in UUO kidneys. Our findings that
GADD45g peaked as early as 6 h post-UUO suggest that
GADD45g activation may be an early, upstream event in the
pathogenesis of tubular injury. Given that majority of the
tubules remain undilated at this early time of UUO, such an
early peak is consistent with our in situ hybridization findings
where GADD45g was strongly induced even in the undilated
tubules.
Recent studies have presented evidence linking GADD45
proteins to activation of JNK and p38 MAPK. It has been
demonstrated that GADD45a, -b, and -g mediate activation of
the p38/JNK pathways, via MTK1/MEKK4, in response to
environmental stresses in COS cells.2 Accordingly, GADD45a
has been shown to be required for p38 MAPK activation in
mouse embryonic fibroblasts.14 Other studies have shown that
GADD45b and GADD45g are implicated in the activation of
p38 and/or JNK in subsets of T cells.15,16 By contrast, several
other studies have not confirmed these results and have
reported conflicting findings. The observations that the
induction of the GADD45 proteins was delayed relative to
JNK/p38 activation in mouse fibroblasts during acute stress
suggests that induction of JNK/p38 does not depend on these
proteins.17 Accordingly, JNK/p38 activation was not impaired
in the absence of GADD45 expression in GADD45/ mouse
embryonic fibroblasts.18 Furthermore, GADD45b has been
shown to inhibit JNK signaling via blockade of the catalytic
activity of MKK7.19 To explain this discrepancy, it has been
proposed that depending on the cell types, GADD45 proteins
may preferentially interact with particular pathways, leading to
differential regulation of p38/JNK activities.20 To explore the
link between the GADD45g and MAPK proteins in renal
tubular cells, we overexpressed GADD45g in HRE cells that are
of kidney tubular origin; we found that only p38 was
significantly activated by the GADD45g protein. Indeed, an
increasing number of studies have suggested that p38 MAPK
activation contributes to pathogenesis of kidney disease. In
cultured renal tubular cells, p38 has been shown to mediate
TGF-b1-induced generation of reactive oxygen species,21 tumor
necrosis factor-a production in ischemic stress,22 and TGF-b1-
induced generation of procollagen-Ia1.23 In rodent models,
p38 activation has been associated with renal inflammation
and fibrosis.24–26 Moreover, it has been demonstrated that p38
activation contributed to the pathogenesis of various progressive
kidney diseases in humans.27,28
Table 1 | Continued
Genes
GenBank
accession Fold±s.d.
Phosphoglycerate mutase 1 (brain) (PGAM1), mRNA NM_002629.2 2.33±0.83
Guanine nucleotide-binding protein (G protein), g-10 (GNG10), mRNA NM_001017998.1 2.33±0.71
Actin, g-1 (ACTG1), mRNA NM_001614.2 2.32±0.94
p53 target zinc-finger protein (WIG1), transcript variant 2, mRNA NM_152240.1 2.29±0.48
Filamin A, a (actin-binding protein 280) (FLNA), mRNA NM_001456.1 2.28±0.43
LanC lantibiotic synthetase component C-like 1 (bacterial) (LANCL1), mRNA NM_006055.1 2.26±0.22
Ribosomal protein, large, P0 (RPLP0), transcript variant 1, mRNA NM_001002.3 2.25±0.57
Nucleosome assembly protein 1-like 1 (NAP1L1), transcript variant 1, mRNA NM_139207.1 2.23±0.44
Matrilin 2 (MATN2), transcript variant 2, mRNA NM_030583.2 2.19±0.14
Cingulin-like 1 (CGNL1), mRNA NM_032866.3 2.19±0.16
EF-hand domain family, member D1 (EFHD1), mRNA NM_025202.2 2.19±0.14
Integrin, b1 (fibronectin receptor, b-polypeptide, antigen CD29 includes MDF2, MSK12) (ITGB1), transcript variant 1E,
mRNA
NM_133376.1 2.18±0.77
Tensin 3 (TNS3), mRNA NM_022748.9 2.18±0.16
Immunoglobulin superfamily, member 4 (IGSF4), mRNA NM_014333.2 2.16±0.32
Chromosome 9 open reading frame 58 (C9orf58), transcript variant 1, mRNA NM_031426.2 2.16±0.08
Transmembrane protein 14A (TMEM14A), mRNA NM_014051.2 2.15±0.21
Collagen, type XI, a1 (COL11A1), transcript variant B, mRNA NM_080629.1 2.15±0.31
Integrin, aV (vitronectin receptor, a-polypeptide, antigen CD51) (ITGAV), mRNA NM_002210.2 2.14±0.53
Nuclear factor I/X (CCAAT-binding transcription factor) (NFIX), mRNA NM_002501.2 2.14±0.20
Transmembrane protein 123 (TMEM123), mRNA NM_052932.1 2.13±0.60
ADP-ribosylation factor-like 6 interacting protein (ARL6IP), mRNA NM_015161.1 2.12±0.29
Zinc-finger protein 503 (ZNF503), mRNA NM_032772.3 2.11±0.20
Chromosome 2 open reading frame 28 (C2orf28), transcript variant 2, mRNA NM_080592.2 2.11±0.10
Adaptor-related protein complex 1, s1 subunit (AP1S1), transcript variant 1, mRNA NM_001283.2 2.10±0.71
Transgelin 2 (TAGLN2), mRNA NM_003564.1 2.09±0.85
Hypoxia-inducible factor 1, a-subunit (basic helix–loop–helix transcription factor) (HIF1A), transcript variant 1, mRNA NM_001530.2 2.07±0.78
Thyroid-hormone receptor interactor 6 (TRIP6), mRNA NM_003302.1 2.07±0.12
Calsyntenin 2 (CLSTN2), mRNA NM_022131.1 2.03±0.09
Family with sequence similarity 84, member B (FAM84B), mRNA NM_174911.3 2.02±0.50
COMM domain containing 6 (COMMD6), transcript variant 2, mRNA NM_203495.1 2.02±0.38
Arachidonate 5-lipoxygenase-activating protein (ALOX5AP), mRNA NM_001629.2 2.01±0.15
Latent transforming growth factor-b-binding protein 3 (LTBP3), mRNA NM_021070.2 2.01±0.45
GADD45g, Growth Arrest and DNA Damage-45g.
Gene expression of human renal epithelial cells overexpressing GADD45g (n=4) was compared with that of control human renal epithelial cells infected with LacZ-containing
adenoviruses (n=4). The values shown are the means of the fold ratios of (GADD45g/LacZ)±s.d. Genes, which displayed a greater than twofold difference, are shown.
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Additionally, we found that GADD45g stimulates the
expression of chemokines including CCL20, CX3CL1, and
IL-8. CCL20 is a molecule mainly expressed by epithelial cells.
CCL20 plays an important role under inflammatory condi-
tions by chemoattracting immature dendritic cells, T cells,
and B cells.29 CCL20 expression was markedly increased in
renal tubular epithelium during allograft rejection episodes,
which suggests CCL20 attracts inflammatory cells to the
kidney.30 CX3CL1 is a transmembrane molecule with an
extracellular chemokine domain and mucin stalk. Soluble
CX3CL1 promotes chemotaxis of target leucocytes, whereas
the membrane-anchored form function as an adhesion
molecule for monocytes, natural killer cells, and subsets of
CD8þ T cells. It has been shown that CX3CL1 enhanced
leukocyte adhesion to the luminal surface of renal tubular
cells.31 Accordingly, expression of CX3CL1 was increased by
tubular epithelial cells in acute renal allograft rejection, and
this correlated with infiltrating leukocyte subsets.32 In
addition, CX3CL1 was upregulated by albumin overload in
cultured renal tubular cells.33 IL-8 is a member of the CXC
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Figure 6 | Enhanced production of chemokines and fibrosis related molecules by GADD45c in human renal epithelial cells. (a) After a
24-h incubation with adenoviral vectors, cells were harvested for reverse transcription-PCRs. Target gene product amounts were normalized
to those of GAPDH, and the results were expressed as fold changes compared with LacZ controls, n¼ 4 for each experimental group.
(b) After a 24-h incubation of adenoviral vectors, cell culture media were harvested for enzyme-linked immunosorbent assay. The protein
levels were corrected for total protein amount of the cell monolayer, n¼ 8 for each experimental group. Data are mean±s.e.m.;
*Po0.05, **Po0.01 compared with LacZ controls (black bar). CCL20, chemokine (C–C motif) ligand 20; CX3CL1, chemokine (C–X3–C
motif) ligand 1; IL-8, interleukin 8; MMP, matrix metalloproteinase; TGF-b1, transforming growth factor-b1; BMP2, bone morphogenetic
protein 2; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
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chemokine family and causes chemotaxis of neutrophils and
T-lymphocytes.34 In human glomerular diseases, IL-8 was
increased in patients’ urine35 and in renal tissue.36 In
addition, a pathogenetic role of IL-8 in antineutrophil
cytoplasmic antibody-associated glomerulonephritis has been
addressed.37
We also found that GADD45g induces the upregulation of
fibrosis-related factors, including MMP1; MMP9 and
MMP10; decorin; TGF-b1; and BMP2. It has historically
been considered that MMPs degrade matrix, thereby redu-
cing renal fibrosis. However, recent studies challenge such a
concept. A decrease in MMP9 by knockout of tissue-type
plasminogen activator preserved the integrity of tubular
basement membrane in the obstructed kidneys.38 Similarly, it
has been shown that MMP9 disrupted cell barrier function in
the kidney cells.39 Furthermore, transgenic renal tubular
expression of MMP2 produced tubular atrophy, fibrosis, and
renal failure in the kidney.40 TGF-b is a multifunctional
cytokine that has been studied extensively as a mediator of
kidney fibrosis.41 Decorin is an extracellular proteoglycan,
which binds TGF-b1, hence it has been suggested that
decorin neutralizes the profibrotic effect of TGF-b1.42
However, accumulating studies showed that decorin actually
contributes to development of glomerular and tubulointer-
stitial fibrosis.43,44 Lastly, increased BMP2 production in
response to high glucose45 and induction of reactive oxygen
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Figure 7 | The effect of GADD45c on HRE cell apoptosis and proliferation. (a, b) GADD45g did not induce apoptosis in HRE cells.
The cells were incubated with adenoviral vectors containing the GADD45g gene or the control LacZ gene at an MOI of 500 for 24 h.
(a) TUNEL staining. TUNEL-positive apoptotic cells were not visualized in HRE cells overexpressed with LacZ or GADD45g. For positive
controls, DNA strand breaks were induced by DNaseI. (b) Western blot analysis for PARP cleavage. PARP cleavage was not observed;
only the intact PARP (116 kDa), and not the cleaved form (89 kDa), was observed in HRE cells overexpressed with LacZ or GADD45g.
(c) GADD45g significantly reduced HRE cell proliferation. After a 24-h incubation with adenoviral vectors, cells were labeled with BrdU.
LacZ 250 served as controls. Values are expressed as percentage of controls and are means±s.e. of three independent experiments, each
of which used five replicate wells per each group. *Po0.05, **Po0.01 compared with LacZ controls. L represents LacZ and G represents
GADD45g. Each number following L or G represents an MOI. PARP, poly(ADP-ribose) polymerase; TUNEL, terminal deoxynucleotidyl
transferase (TdT)-mediated dUTP-biotin nick-end labeling; BrdU, 5-bromo-20-deoxyuridine.
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species by BMP2 in glomerular cells suggest that BMP2 may
contribute to glomerular cell injury.46 To further elucidate the
link between GADD45g and inflammatory and fibrogenic
mediators, we knocked down the GADD45g gene in the
kidney using in vivo infusion of siRNA and were able to
demonstrate that silencing of GADD45g gene significantly
blocks upregulation of CCL20, CX3CL1, CINC-1, and TGF-
b1 in UUO kidneys. We also demonstrated that silencing of
GADD45g gene significantly reduces inflammatory cell
infiltration in UUO kidneys.
In this study, we show that GADD45g is upregulated in
UUO and is expressed in kidney biopsy tissue obtained from
patients with chronic glomerulonephritis. We further provide
in vitro and in vivo evidence that GADD45g regulates various
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Figure 8 | GADD45c siRNA reduced the expression of chemokines, TGF-b1, and p-p38 MAPK. (a) The mRNA expression of CCL20,
CX3CL1, CINC-1, and TGF-b1 was significantly increased in the kidneys 2 days after UUO (gray bars) compared with sham-operated controls
(black bars). The western blot shows that p-p38 MAPK was increased significantly in the kidneys 2 days after UUO compared with
sham-operated controls, n¼ 10–12 for each experimental group. (b) The expression of GADD45g mRNA was significantly decreased in
UUO kidneys treated with GADD45g siRNA. Subsequent competitive PCRs confirmed a 90% reduction of GADD45g mRNA in GADD45g
siRNA-treated kidneys, n¼ 6 for each experimental group. (c) The expression of CCL20, CX3CL1, CINC-1, and TGF-b1 was significantly
decreased in GADD45g siRNA-treated UUO kidneys (dark gray bars) compared with the control UUO kidneys treated with PBS (black bars) or
negative control siRNA (light gray bars). The western blot shows that p-p38 MAPK was significantly reduced by GADD45g siRNA infusion,
n¼ 6 for each experimental group. Data are mean±s.e.m.; *Po0.05, **Po0.01 compared with controls. UUO, unilateral ureteral
obstruction; PBS, phosphate-buffered saline; CCL20, chemokine (C–C motif) ligand 20; CX3CL1, chemokine (C–X3–C motif) ligand 1;
CINC-1, cytokine-induced neutrophil chemoattractant-1 (rat homolog for human IL-8); TGF-b1, transforming growth factor-b1;
GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
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molecules that have been implicated in the pathogenesis of
kidney disease. Further studies are warranted to determine
the role of GADD45g in the pathogenesis of kidney disease.
MATERIALS AND METHODS
Animal surgery
Male Wistar rats (Japan SLC, Hamamatsu, Japan) weighing
250–300 g were used for UUO or a sham operation. After anesthesia,
the left kidney and the ureter were exposed by an abdominal
incision and the left ureter was ligated with 4-0 silk. The sham
operation for control kidneys consisted of a similar abdominal
incision and visualization of the left ureter without further
manipulation. The harvested kidneys were bisected and cortical
tissues were immediately snap frozen in liquid nitrogen and kept at
70 1C until required. For in situ hybridization, the halved kidneys
were immediately fixed in 4% paraformaldehyde. All animal
experiments were undertaken in accordance with the guidelines of
the animal committee of our institution.
Differential display analysis
Differential display was performed using a Gene Fishing DEG kit
(Seegene, Seoul, South Korea) according to the manufacturer’s
instructions. Total RNA was extracted from the rat kidney harvested 1
day following UUO. The unobstructed kidney on the other side
served as a control. First-strand complementary DNA was synthesized
by reverse transcription using the annealing control primer, dT-ACP1
(50-CTGTGAATGCTGCGACTACGATXXXXX(T)18-30), and then
PCRs were performed with combinations of an arbitrary ACP
(ACP01-ACP20) and dT-ACP2 (50-CTGTGAATGCTGCGACTACG
ATXXXXX(T)15-3
0). The PCR products were separated by 2% agarose
gel electrophoresis. Differentially expressed genes were cloned into a
TOPO TA cloning vector (Invitrogen, Carlsbad, CA, USA); the inserts
were then sequenced.
In situ hybridization
To synthesize DIG-labeled cRNA probes, a DNA fragment contain-
ing bases þ 341 to þ 782 (442 bp) of rat GADD45g (GenBank
accession no. AB020978) were ligated into the XbaI–XmaI restriction
sites of a vector pSPT18 (Roche, Mannheim, Germany), which
contains SP6 and T7 polymerase sites flanking the cloned insert.
After linearization with XbaI or XmaI, the DNA insert was
transcribed into antisense and sense cRNA probes in the reaction
mixture containing DIG-11-UTP by T7 or SP6 RNA polymerase,
respectively. Sections (7 mm) were cut from paraffin-embedded
blocks, dewaxed, and then permeabilized using 12.5mg ml1 RNase-
free proteinase K for 30 min at 37 1C. The sections were refixed with
4% paraformaldehyde for 5 min at 4 1C, treated with 0.25% acetic
anhydride in 0.1 M triethanolamine (pH 8), and then incubated in
pre-hybridization buffer (4 saline-sodium citrate, 50% deionized
formamide). We then applied 150 ng DIG-labeled sense or antisense
probes in 75 ml hybridization buffer (40% deionized formamide,
10% dextran sulfate, 1 Denhardt’s solution, 4 SSC, 10 mM DTT,
1 mg ml1 yeast t-RNA, 1 mg ml1 salmon sperm DNA) to the
sections, coverslipped, and then incubated them at 42 1C for
overnight in a humid chamber. The sense probe served as control.
After hybridization, the sections were treated with 20 mg ml1 RNase
A in NTE buffer (500 mM NaCl, 10 mM Tris, 1 mM EDTA, pH 8) for
30 min at 37 1C. After incubation with blocking solution (0.1%
Triton X-100, 2% normal sheep serum), the sections were incubated
with 1:500 anti-DIG alkaline phosphatase Fab fragments in blocking
solution for 2 h at room temperature. We then developed color with
nitro-blue tetrazolium and 5-bromo-4-chloro-3-indolyl phosphate
in buffer (100 mM Tris-HCl (pH 9.5), 100 mM NaCl, 50 mM MgCl2)
containing 5 mM levamisole.
RNA isolation
Kidney specimens were homogenized in Trizol reagent (Invitrogen)
using a glass–Teflon homogenizer. RNA was extracted with chloro-
form, precipitated with isopropanol, washed with 75% ethanol, and
then redissolved in TE buffer. The isolated RNA was quantified
spectrophotometrically.
Reverse transcription
After removing contaminated DNA from the isolated RNA using
DNaseI (Invitrogen), 1 mg of total RNA was reverse transcribed
into cDNA in 20 ml reaction mixtures containing 200 U of Moloney
murine leukemia virus reverse transcriptase; 100 ng per reaction of
random hexanucleotide primers; and 0.5 mM each of dNTPs, dATP,
dCTP, dGTP, and dTTP. The reaction mixture was then incubated at
37 1C for 1 hour and at 65 1C for 10 min to deactivate the reverse
transcriptase.
Polymerase chain reactions
Competitive PCRs were performed for GADD45g and GAPDH of
rat kidneys using the competitor constructs as described pre-
viously.47,48 Semiquantitative PCRs were performed for multiple
gene analysis of HRE cells. Individual PCRs was performed over
28–33 cycles using a Perkin Elmer 9600 thermocycler. The
amplification profile typically consisted of denaturation at 94 1C
for 20 s, primer annealing at 57 1C for 30 s, and primer extension at
72 1C for 20 s. Target gene-specific primers are shown in Table 2.
The target gene product amounts were normalized to those of
GAPDH.
Immunohistochemistry
For antigen retrieval, the 4-mm paraffin sections obtained from
human biopsy samples were heated in citrate buffer (pH 6) in a
microwave oven , and then incubated with the GADD45g primary
antibody for 1 h at room temperature in a humidified chamber. For
immunostaining of ED1 (¼CD68, a specific monocyte/macrophage
marker), the paraffin sections obtained from rat kidneys were
treated with 0.1% proteinase K (Sigma, St Louis, MO, USA) for
30 min and incubated with ED1 primary antibody (Serotec, Oxford,
UK) for 1 h at 37 1C in a humidified chamber. The sections were
Figure 9 | ED1 immunostaining to assess monocyte/
macrophage infiltration in the interstitium. ED1-positive cells
(brown-red cytoplasmic staining) were significantly reduced in
UUO kidneys treated with GADD45g siRNA (a) compared with the
control UUO kidneys treated with negative control siRNA (b).
Original magnification  400.
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Table 2 | Primers used in the PCRs
Primers (expected size) Sequences GenBank accession
GAPDH, rat (390 bp) F: 50-TGTTCCAGTATGACTCTACCC-30 AF106860
R: 50-TCATGAGCCCTTCCACGATG-30
GADD45g, rat (378 bp) F: 50-ACTCTGGAAGAAGTCCGTGG-30 AB020978
R: 50-TTCATTAGGGTTCGAAATGAGG-30
GADD45a, rat (314 bp) F: 50-AGGAAGTGCTCAGCAAGGCT-30 NM_024127
R: 50-CGTCACCAGCACACAGTGTA-30
GADD45b, rat (302 bp) F: 50-TCAGAAGATGCAGGCGGTGA-30 NM_001008321
R: 50-CCTCGTTTGTGCCTAGAGTC-30
CINC-1, rat (669 bp) F: 50-CTCCAGCCACACTCCAACAGA-30 NM_030845
R: 50-CACCCTAACACAAAACACGAT-30
CX3CL1, rat (160 bp) F: 50-TTTCATCTGTGTACTCTGCTGGC-30 NM_030845
R: 50-GTCTCGTCTCCAGGATGATGG-30
CCL20, rat (301 bp) F: 50-GATGGAATTGGACAAGCCC-30 NM_019233
R: 50-AAGGGCCATATAAACTTACTGC-30
GAPDH (299 bp) F: 50-GTCGGAGTCAACGGATTTGG-30 NM_002046
R: 50-ATGGTGGTGAAGACGCCAGT-30
CCL20 (270 bp) F: 50-GTGCTGTACCAAGAGTTTGCT-30 NM_004591
R: 50-TTACTGAGGAGACGCACAATAT-30
CX3CL1 (347 bp) F: 50-TTGGCCACCTTCTGCCATCT-30 NM_002996
R: 50-AGGACCACAGACTCGTCCAT-30
IL-8 (258 bp) F: 50-CTGATTTCTGCAGCTCTGTGT-30 NM_000584
R: 50-TGAATTCTCAGCCCTCTTCAAA-30
IL-11 (355 bp) F: 50-ACCACAACCTGGATTCCCTG-30 NM_000641
R: 50-CAGTCAAGTGTCAGGTGCAG-30
MMP1 (432 bp) F: 50-GTATTGGAGGGGATGCTCATT-30 NM_002421
R: 50-ATTCGTAAGCAGCTTCAAGCC-30
MMP10 (240 bp) F: 50-ACTCATTCACAGAGCTCGCC-30 NM_002425
R: 50-TCCAGTGGGATCTTCGCCAA-30
BMP2 (351 bp) F: 50-CCTGCAACAGCCAACTCGAA-30 NM_001200
R: 50-GCTGGACTTAAGGCGTTTCC-30
Decorin (246 bp) F: 50-GTGGTCCAGTGTTCTGATTTG-30 NM_133504
R: 50-GAAACTCAATCCCAACTTAGCC-30
Integrin-a5 (351 bp) F: 50-TGCACCACCAGCAAAAACGG-30 NM_002205
R: 50-CTAGGATGATGATCCACAGTG-30
Thrombospondin 1 (320 bp) F: 50-GGAGAATGCTGAGTTGGACG-30 NM_003246
R: 50-CCATGCTGGACAGCTCATCA-30
Integrin-b1 (382 bp) F: 50-ACCACAGCAGTTGGTTTTGCG-30 NM_133376
R: 50-AGATATGCGCTGTTTTCCAACA-30
Collagen XI (360 bp) F: 50-ATCACAGGTGATCCCAAGGC-30 NM_080629
R: 50-ATTTGGCTCATTTGTCCCAGAA-30
Collagen I (348 bp) F: 50-TGCCGTGACCTCAAGATGTG -30 NM_000088
R: 50-CACGCTGTTCTTGCAGTGGTA-30
Collagen III (440 bp) F: 50-TGGAGGTGAAAAAGCTGGCG-30 NM_000090
R: 50-CCAGCTGCACATCAAGGACA-30
Fibronectin (501 bp) F: 50-AGGTAGCAGCACAGAACTCAA-30 NM_212482
R: 50-CATCTCACCAGGACAGTAGAA-30
MMP1 (392 bp) F: 50-ACAACTTACATCGTGTTGCGG-30 NM_002421
R: 50-GACTTCATCTCTGTCGGCAAA-30
Collagen IV (391 bp) F: 50-GTATTGGTGGCTCTCCAGGA-30 NM_001845
R: 50-CCTGGAAATCCTCTTGGACC-30
MMP9 (380 bp) F: 50-TGCCTGCAACGTGAACATCTT-30 NM_004994
R: 50-TCTGCGCCTTCACGTCGAAC-30
MCP-1 (292 bp) F: 50-AAAGTCTCTGCCGCCCTTCT-30 X14768
R: 50-TCTTCGGAGTTTGGGTTTGCT-30
CTGF (320 bp) F: 50-CCCGGGTTACCAATGACAAC-30 NM_001901
R: 50-GCAGGCACAGGTCTTGATGA-30
VEGFB (320 bp) F: 50-CACCAGAGGAAAGTGGTGTC-30 NM_003377
R: 50-CTGTCTGGCTTCACAGCACT-30
PAI-1 (360 bp) F: 50-AAAGAGGTGCCTCTCTCTGC-30 M16006
R: 50-GACCACAAAGAGGAAGGGTC-30
VEGFA (370 bp) F: 50-CTGAGGAGTCCAACATCACC-30 NM_001025366
R: 50-AACTCAAGCTGCCTCGCCTT-30
MMP2 (347 bp) F: 50-TTGATGCGGTATACGAGGCC-30 NM_004530
R: 50-GGCACCCTTGAAGAAGTAGC -30
BMP2, bone morphogenetic protein 2; CCL20, chemokine (C–C motif) ligand 20; CINC-1, cytokine-induced neutrophil chemoattractant-1; CTGF, connective tissue growth
factor; CX3CL1, chemokine (C–X3–C motif) ligand 1; F, forward primers; GADD45g, Growth Arrest and DNA Damage-45g; GAPDH, glyceraldehyde-3-phosphate dehydrogenase;
IL, interleukin; MCP-1, monocyte chemotactic protein-1; MMP, matrix metalloproteinase; PAI-1, plasminogen activator inhibitor-1; R, reverse primers; TGF-b1, transforming
growth factor-b1; VEGFA, vascular endothelial growth factor A; VEGFB, vascular endothelial growth factor A.
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then incubated with biotinylated secondary antibodies (Dako,
Carpinteria, CA, USA) followed by peroxidase-labeled streptavidin.
Sections were developed with diaminobenzidine and counterstained
with hematoxylin. All protocols for obtaining human samples were
approved by the institutional review board of our institution.
Cell culture
Primary HRE cells (Cambrex, Walkersville, MD, USA) were
prepared and maintained in renal epithelial basal medium with
recommended supplements included in the REGM Singlequot
Bulletkit (Cambrex). Renal epithelial basal medium supplemented
only with 0.5% fetal bovine serum was used for serum starvation.
Western blot analysis
Two wells of a six-well plate were pooled for each analytical sample
in all cases. Equal amounts of total protein (20–30 mg) were
subjected to 6–15% acrylamide gel sodium dodecyl sulfate-
polyacrylamide gel electrophoresis, blotted with primary antibodies
for GADD45g (sc-8778; Santa Cruz Biotechnology, Santa Cruz, CA,
USA) or MAPK proteins (Cell Signaling, Danvers, MA, USA), and
then incubated with peroxidase-conjugated secondary antibodies.
We then detected the proteins by enhanced chemiluminescence
(Amersham, Piscataway, NJ, USA). Band intensity was analyzed
using the Scion Image software alpha 4.0.3.2 (Scion Corp.,
Frederick, MD, USA).
Microarray analysis
After 24 h of serum starvation, HRE cells were infected with Ad-
GADD45g at an MOI of 50 (n¼ 4, sample group) and with Ad-LacZ
at an MOI of 100 (n¼ 4, control group). After 24 h of incubation,
cells were harvested and total RNA was isolated as described above.
Two wells of the six-well plate were pooled for each analytical
sample. Biotinylated cRNA was prepared using the Illumina
amplification kit (Ambion, San Diego, CA, USA) and was purified
using RNAeasy columns (Qiagen, Valencia, CA, USA). The product
was hybridized to Sentrix Human Ref-8 Expression Beadchips
(Illumina, San Diego, CA, USA) and was detected with streptavidin-
Cy3. The arrays were scanned using the Illumina Bead Station 500x
array reader (Illumina). The scanned images were analyzed using the
BeadStudio software (Illumina).
Enzyme-linked immunosorbent assay
After 24 h of serum starvation, HRE cells were infected with Ad-
GADD45g at an MOI of 50 (n¼ 8, sample group) and with Ad-LacZ
at an MOI of 100 (n¼ 8, control group). After 24 h of incubation,
cell culture media were collected and analyzed for CCL-20, CX3CL1,
and IL-8 using commercially available enzyme-linked immunosor-
bent assay kits according to the manufacturer’s specifications (R&D
Systems, Minneapolis, MN, USA).
Apoptosis assay
Terminal deoxynucleotidyl transferase (TdT)-mediated dUTP–bio-
tin nick-end labeling staining was performed to label DNA strand
breaks generated during apoptosis with fluorescein isothiocyanate-
conjugated dUTP (Roche). Cells grown on coverslips were incubated
in permeabilization solution (0.1% Triton X-100 in 0.1% sodium
citrate) and then with mixture of TdT and labeled dNTP. For
positive controls, DNA strand breaks were induced by incubating
fixed and permeabilized cells with 10 U of DNaseI. The apoptotic
cells were visualized by fluorescence microscopy (Axiostar plus; Carl
Zeiss, Jena, Germany). We also observed apoptosis by western
blotting for PARP cleavage using the monoclonal anti-PARP
antibody (Cell Signaling).
Cell proliferation assay
The effect of GADD45g on HRE cell proliferation was determined
using the BrdU Labeling and Detection kit (Roche) according to the
manufacturer’s instructions. Briefly, cells were incubated with
various concentrations of Ad-GADD45g for 24 h, the medium was
then replaced, and cells were incubated with 10 mM BrdU for 18 h.
BrdU-labeled DNA was detected using an anti-BrdU antibody
conjugated with peroxidase and visualized with a soluble chromo-
genic substrate. Optical density was measured using a microplate
reader at 405 nm.
In vivo silencing of the GADD45c gene
We performed in vivo gene silencing based on hydrodynamic
injection of siRNAs, which has been used successfully to silence
target gene expression in the kidney.6–8 The sense and antisense
strands of siRNA targeted to GADD45g were annealed and dissolved
in RNase-free PBS. Rats were rapidly injected into the tail vein with
500 mg GADD45g siRNA or negative control siRNA (Bioneer,
Daejeon, Korea) in 6 ml PBS or PBS only. The sequences of siRNA
were as follows: GADD45g siRNA: CUGUUCGUGGAUCGCAC
AAdTdT (sense), UUGUGCGAUCCACGAACAGdTdT (antisense);
negative control siRNA: 50-CCUACGCCACCAAUUUCGUdTdT-30
(sense), 50-ACGAAAUUGGUGGCGUAGGdTdT (antisense). Ureters
were ligated on the following day and the kidneys were harvested
2 days after UUO.
Statistical analysis
Data are expressed as means±s.e.m. (s.d. for microarray results).
Unpaired t-test was used to compare continuous variables between
two groups. A P-value of o0.05 was considered significant.
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